These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 38035854)

  • 1. Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable Viremia.
    Benlarbi M; Richard J; Bourassa C; Tolbert WD; Chartrand-Lefebvre C; Gendron-Lepage G; Sylla M; El-Far M; Messier-Peet M; Guertin C; Turcotte I; Fromentin R; Verly MM; Prévost J; Clark A; Mothes W; Kaufmann DE; Maldarelli F; Chomont N; Bégin P; Tremblay C; Baril JG; Trottier B; Trottier S; Duerr R; Pazgier M; Durand M; Finzi A
    J Infect Dis; 2024 Mar; 229(3):763-774. PubMed ID: 38035854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmatic HIV-1 soluble gp120 is associated with immune dysfunction and inflammation in ART-treated individuals with undetectable viremia.
    Benlarbi M; Richard J; Bourassa C; Tolbert WD; Chartrand-Lefebvre C; Gendron-Lepage G; Sylla M; El-Far M; Messier-Peet M; Guertin C; Turcotte I; Fromentin R; Verly MM; Prévost J; Clark A; Mothes W; Kaufmann DE; Maldarelli F; Chomont N; Bégin P; Tremblay C; Baril JG; Trottier B; Trottier S; Duerr R; Pazgier M; Durand M; Finzi A; ;
    medRxiv; 2023 Aug; ():. PubMed ID: 37645879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.
    Mori T; Boyd MR
    Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies.
    Mondor I; Moulard M; Ugolini S; Klasse PJ; Hoxie J; Amara A; Delaunay T; Wyatt R; Sodroski J; Sattentau QJ
    Virology; 1998 Sep; 248(2):394-405. PubMed ID: 9721247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A virus-envelope paired competitive assay to study entry efficiency of human immunodeficiency virus type 1 in vitro.
    Schwalbe B; Hauser H; Schreiber M
    J Virol Methods; 2014 Sep; 205():91-8. PubMed ID: 24859049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
    Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
    J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.
    Bongertz V; Ouverney EP; Fernandez SC; Grinsztejn B; Veloso V; Couto-Fernandez JC; Pilotto JH; Morgado MG
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):817-25. PubMed ID: 18060317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
    Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
    Moore JP; Cao Y; Ho DD; Koup RA
    J Virol; 1994 Aug; 68(8):5142-55. PubMed ID: 8035514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
    Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.
    Green TD; Montefiori DC; Ross TM
    J Virol; 2003 Feb; 77(3):2046-55. PubMed ID: 12525639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.
    Hunt PW; Brenchley J; Sinclair E; McCune JM; Roland M; Page-Shafer K; Hsue P; Emu B; Krone M; Lampiris H; Douek D; Martin JN; Deeks SG
    J Infect Dis; 2008 Jan; 197(1):126-33. PubMed ID: 18171295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens.
    DeVico A; Fouts T; Lewis GK; Gallo RC; Godfrey K; Charurat M; Harris I; Galmin L; Pal R
    Proc Natl Acad Sci U S A; 2007 Oct; 104(44):17477-82. PubMed ID: 17956985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines.
    Rychert J; Strick D; Bazner S; Robinson J; Rosenberg E
    AIDS Res Hum Retroviruses; 2010 Oct; 26(10):1139-45. PubMed ID: 20722464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection.
    Boyd A; Meynard JL; Morand-Joubert L; Michon A; Boccara F; Bastard JP; Samri A; Haddour N; Mallat Z; Capeau J; Desvarieux M; Girard PM;
    PLoS One; 2014; 9(11):e113876. PubMed ID: 25415323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Tat immunity defines CD4
    Tripiciano A; Picconi O; Moretti S; Sgadari C; Cafaro A; Francavilla V; Arancio A; Paniccia G; Campagna M; Pavone-Cossut MR; Sighinolfi L; Latini A; Mercurio VS; Pietro MD; Castelli F; Saracino A; Mussini C; Perri GD; Galli M; Nozza S; Ensoli F; Monini P; Ensoli B
    EBioMedicine; 2021 Apr; 66():103306. PubMed ID: 33839064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41.
    O'Keefe BR; Shenoy SR; Xie D; Zhang W; Muschik JM; Currens MJ; Chaiken I; Boyd MR
    Mol Pharmacol; 2000 Nov; 58(5):982-92. PubMed ID: 11040045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker.
    Yuan W; Bazick J; Sodroski J
    J Virol; 2006 Jul; 80(14):6725-37. PubMed ID: 16809278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individuals.
    Lichterfeld M; Gandhi RT; Simmons RP; Flynn T; Sbrolla A; Yu XG; Basgoz N; Mui S; Williams K; Streeck H; Burgett-Yandow N; Roy G; Janssens M; Pedneault L; Vandepapelière P; Koutsoukos M; Demoitié MA; Bourguignon P; McNally L; Voss G; Altfeld M
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):1-9. PubMed ID: 21963936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.